Status:
COMPLETED
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Hepatitis C, Chronic
Eligibility:
All Genders
18+ years
Brief Summary
This prospective observational study will evaluate the efficacy and safety of two approved pegylated interferon-based direct acting antiviral triple therapies in patients with chronic hepatitis C geno...
Eligibility Criteria
Inclusion
- Adult patients, \>/= 18 years of age
- Chronic hepatitis C, genotype 1
- Receiving pegylated interferon-based direct acting antiviral therapy (pegylated interferon and ribavirin plus either telaprevir or boceprivir) in accordance with local standard of care and US labeling
Exclusion
- Contraindications per US labels
Key Trial Info
Start Date :
January 31 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 31 2014
Estimated Enrollment :
672 Patients enrolled
Trial Details
Trial ID
NCT01508130
Start Date
January 31 2012
End Date
March 31 2014
Last Update
April 10 2017
Active Locations (66)
Enter a location and click search to find clinical trials sorted by distance.
1
Cooper Green Hospital
Birmingham, Alabama, United States, 35233
2
Univ. of Alabama at Birmingham; The Kirklin Clinic
Birmingham, Alabama, United States, 35233
3
Liver Wellness Center
Little Rock, Arkansas, United States, 72205
4
Loma Linda University Medical Center and Liver Center
Loma Linda, California, United States, 92354